Cardiol Therapeutics nears full enrollment for Phase III MAVERIC trial of CardiolRx in recurrent pericarditis

• Cardiol Therapeutics plans to complete enrollment in its pivotal Phase III MAVERIC trial testing CardiolRx for reducing the risk of recurrent pericarditis.
• The strategy centers on using the newly published Phase II evidence base to support the Phase III program design and execution.
• Management is positioning CardiolRx as a potential non-immunosuppressive option for patients with recurrent disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001279569-26-000670), on July 14, 2026, and is solely responsible for the information contained therein.